Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122447) titled 'Study on Individualized Dose Reduction Strategies for Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis' on April 14.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: The First Affiliated Hospital of Army Medical University
Condition:
atopic dermatitis
Intervention:
Dose reduction group:None
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-04-15
Target Sample Size: Dose reduction group:36;Extended dosing interval group:42;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=316359...